INTRODUCTION
============

Rheumatoid arthritis is the most common autoimmune disease found in about 1% of adults worldwide. Rheumatoid arthritis is caused by neutrophils, macrophages, T cells, B cells and dendritic cells infiltrating the synovium of joints and causing inflammation, it causes damage to bone and disability. Finally, it induces systemic complications such as cardiovascular and cardiopulmonary dysfunction, and reduces life expectancy by about 3--10 years ([@b3-jer-12-6-610]; [@b27-jer-12-6-610]). Rheumatoid arthritis is 2 to 3 times more common in females than males ([@b3-jer-12-6-610]). Although the pathogenesis of rheumatoid arthritis has not yet been elucidated, it is known that the interaction of genetic and environmental factors influences congenital and adaptive immunity, resulting in systemic inflammation ([@b27-jer-12-6-610]).

Vitamin D not only plays a major role in the regulation of bone mineral homeostasis but also plays a role in cell function such as cell proliferation, differentiation, apoptosis, and angiogenesis ([@b1-jer-12-6-610]).

Recently, appropriate level of vitamin D has been reported to reduce the risk of some chronic inflammatory or autoimmune conditions such as various cancers, infectious diseases, type 1 diabetes, multiple sclerosis, and autoimmune rheumatic disease ([@b2-jer-12-6-610]). Calcitriol or 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), an endogenous serum-active metabolite of vitamin D, is a kind of steroid hormone produced by cholesterol. Therefore, calcitriol has immunomodulatory properties such as glucocorticoid and gonadal hormones ([@b10-jer-12-6-610]).

There are reports that low vitamin D intake is associated with the development of rheumatoid arthritis, or low serum vitamin D level is associated with disease activity or physical disability in rheumatoid arthritis ([@b16-jer-12-6-610]; [@b20-jer-12-6-610]; [@b24-jer-12-6-610]; [@b29-jer-12-6-610]). On the other hand, there are reports that vitamin D levels in patients with inflammatory joint disease are not related to arthritis activity ([@b5-jer-12-6-610]; [@b9-jer-12-6-610]).

The purpose of this study was to investigate the effect of vitamin D levels on the prevalence of rheumatoid arthritis in Korean adult women and to investigate the association of vitamin D levels with pain level and quality of life in Korean adult women with rheumatoid arthritis using the Korean National Health and Nutrition Examination Survey (KNHANES) from the [@b21-jer-12-6-610].

MATERIALS AND METHODS
=====================

Subjects
--------

This study analyzed the data of 2008--2014 from KNHANES. The subjects were women aged 19 years or older who completed a health questionnaire on rheumatoid arthritis and evaluation of vitamin D (25-hydroxyvitamin D; 25(OH)D) status.

It was reported that osteoporosis or increased parathyroid hormone affects vitamin D level ([@b4-jer-12-6-610]), and parathyroid hormone has inverse correlation with the conversion of vitamin D (25(OH)D) to active form of vitamin D, calcitriol (1,25(OH)2D3) ([@b26-jer-12-6-610]). Thus, in the present study, patients with osteoporosis were excluded from the study until the year 2012 when health questionnaires and examinations for related items were discontinued. Parathyroid hormone abnormalities were also excluded in cases of over 65 pg/mL, according to the previous study ([@b4-jer-12-6-610]). Vitamin D is metabolized to the active form of calcitriol (1,25 (OH)2D3) in the liver and kidneys ([@b7-jer-12-6-610]), thus, patients with renal insufficiency or liver cirrhosis ([@b1-jer-12-6-610]) or those with thyroid disease or those with creatinine levels above 2.0 mg/dL were also excluded ([@b15-jer-12-6-610]).

Study design
------------

The subjects were divided into whole female or fertile period and postmenopausal period. In each group, subjects were divided into five groups using the 5th quintile according to the serum level of vitamin D. The odds ratios of the five groups of rheumatoid arthritis according to the level of vitamin D in the serum were checked and the degree of pain and quality of life of the rheumatoid arthritis patients were analyzed. Pain intensity was assessed by visual analogue scale (VAS) ranging from 0 to 100, and quality of life was assessed using the EQ-5D questionnaire.

Statistics
----------

KNHANES was recommended to be analyzed by complex sampling design ([@b21-jer-12-6-610]). Thus, in this study, weights of each year were multiplied by the ratio of the surveyed population by year to generate integrated weights.

Demographic information used frequency and descriptive statistics of complex sampling design. The odds ratio of rheumatoid arthritis according to the level of vitamin D was determined by complex sampling design logistic regression. The degree of pain and quality of life of patients with rheumatoid arthritis according to their vitamin D levels were determined by the complex sampling design general linear model.

In the analysis of odds ratio, pain level and quality of life, we compared the value of the 5th group with the highest vitamin D level, and the values of the remaining four groups and found that there was a statistically significant difference. When there is a statistically significant difference, the *P* for trend of the complex sampling design general linear model is conducted to confirm the linear trend.

Age and body mass index are major risk factors for rheumatoid arthritis ([@b28-jer-12-6-610]) and also affect vitamin D level ([@b13-jer-12-6-610]; [@b19-jer-12-6-610]). Thus, age and body mass index were used as covariates to control the effect of age and obesity on the association of rheumatoid arthritis and vitamin D level. In model 1, only age was used as covariate, and in model 2, both age and body mass index were used as covariates.

The values of the continuous variables were expressed as mean (standard error; SE), and the results of complex sampling design logistic regression analysis showed odds ratio and 95% confidence intervals (CIs).

Statistical analysis was performed using IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA). All statistical significances were *P*\<0.05.

RESULTS
=======

Demographic information
-----------------------

A total of 2,162 unweighted subjects were included in the study and their mean vitamin D was 15.80 ng/mL and the prevalence of rheumatoid arthritis was 12.0%. The numbers of unweighted subjects in fertile period female was 1,179, the mean vitamin D was 14.54 ng/mL, and the prevalence of rheumatoid arthritis was 5.7%. The numbers of unweighted subjects in postmenopausal period female was 983, and their mean vitamin D was 17.92 Ng/mL, and prevalence of rheumatoid arthritis was 22.4%, both of which were higher than those of fertile period female ([Table 1](#t1-jer-12-6-610){ref-type="table"}).

Association between rheumatoid arthritis and vitamin D status
-------------------------------------------------------------

The odds ratios of rheumatoid arthritis according to the level of total vitamin D in the whole female was statistically significantly lower in the lowest vitamin D group and the second lowest vitamin D group than in the group with the highest vitamin D before using covariance. However, after using the covariates, all of these statistical differences disappeared.

The results of the subdivided into fertile period female and postmenopausal period female showed that the odds ratio of rheumatoid arthritis according to the level of serum vitamin D was not statistically significant ([Table 2](#t2-jer-12-6-610){ref-type="table"}).

Association between rheumatoid arthritis' VAS and vitamin D status
------------------------------------------------------------------

In whole rheumatoid arthritis female group, the difference in pain level was not statistically significant depending on the level of vitamin D, and also was not statistically significant in fertile period rheumatoid arthritis female group.

In postmenopausal period rheumatoid arthritis female group, the third highest vitamin D group had significantly higher pain intensity before using the covariate than the group with the highest vitamin D.

There was statistically significant difference between the group with the most severe pain and the group with the mildest pain in the models 1 and 2. However, there was no statistically significant difference in the degree of pain compared to the group with the highest vitamin D.

In the *P* for trend, *P*=0.879 before using covariance, *P*=0.702 in model 1 and *P*=0.606 in model 2 were not statistically significant. Thus, the difference in pain level according to the level of vitamin D was not linear ([Table 3](#t3-jer-12-6-610){ref-type="table"}).

Association between rheumatoid arthritis' EQ-5D index and vitamin D status
--------------------------------------------------------------------------

There was no statistically significant difference in the quality of life among the whole rheumatoid arthritis female according to their levels of vitamin D.

In fertile period rheumatoid arthritis female, the group with the lowest vitamin D had significantly lower quality of life before using covariance and model 1 than the group with the highest vitamin D. However, there was no statistically significant difference in model 2. And, in postmenopausal period rheumatoid arthritis female group, the difference in quality of life according to the level of serum vitamin D was not statistically significant ([Table 4](#t4-jer-12-6-610){ref-type="table"}).

DISCUSSION
==========

Vitamin D levels in the body are most important to be produced by exposure to sunlight, which affects sun exposure, including skin pigmentation, clothing style, use of sunscreen, physical activity, and age. However, in case of inadequate exposure to sunlight increases the importance of food intake. And vitamin D levels are also affected by obesity, calcium, and parathyroid hormone ([@b23-jer-12-6-610]). Obesity has been reported to reduce vitamin D ([@b13-jer-12-6-610]), and increasing age also reduces vitamin D, leading to a reduction in vitamin D to about 1/4 of that of younger adults ([@b19-jer-12-6-610]).

However, in this study, postmenopausal period female with higher body mass index and higher age showed higher levels of vitamin D than fertile period female. Meta-analysis of vitamin D levels showed that there were differences according to age and region. Children and adolescent vitamin D levels were lower in the Asia/Pacific region than adults and elderly, however, children and adolescent vitamin D levels were higher in the Middle East/Africa region than adults and elderly ([@b17-jer-12-6-610]). Moreover, in Korea's previous study, serum vitamin D levels were the lowest in the 20s and gradually increased with age up to 60s in both sexes ([@b25-jer-12-6-610]). In industrialized countries, relatively younger women tend to use clothing or sunscreen agents, to reduce exposure to sunlight. In addition, the higher proportion of indoor occupation then undeveloped country may have reduced vitamin D in young cases ([@b25-jer-12-6-610]). The elderly can maintain a sufficient level of vitamin D when exposed to the appropriate amount of ultraviolet light. Therefore, postmenopausal period female with higher occupation rate of occupations with a lot of outdoor activities such as agriculture and a higher rate of participation in outdoor activities such as sports may have a relatively long exposure time to sunlight ([@b23-jer-12-6-610]).

The immune function of vitamin D is mediated by the vitamin D receptor. Vitamin D inhibits proliferation of activated B lymphocytes expressing vitamin D receptors and inhibits proliferation and differentiation of T cells. Vitamin D also has been shown to inhibit the production of interleukin (IL)-2, interferon gamma of T helper (Th) 1 cells and to inhibit the production of IL-17 of Th17 cells. Therefore, vitamin D has been reported to inhibit the proinflammatory response ([@b1-jer-12-6-610]). However, in this study, there was no significant difference in the odds ratio of rheumatoid arthritis according to the level of vitamin D. There have been some preclinical studies that suggest that vitamin D may be helpful in the treatment of Th17 mediated inflammatory diseases such as rheumatoid arthritis ([@b1-jer-12-6-610]).

However, in clinical studies and research results, many cases were not. In cross-sectional studies, there was no difference in the activity of arthritis, C-reactive protein, and erythrocyte sedimentation rate according to serum vitamin D levels in patients with inflammatory arthritis such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis ([@b5-jer-12-6-610]). Preclinical rheumatoid arthritis may be caused by a subclinical inflammatory process as well as a decrease in vitamin D levels due to reduced sun exposure due to decreased physical activity and changes in dietary intake. However, it is unclear whether low levels of vitamin D increase the risk of rheumatoid arthritis or whether inflammatory conditions due to preclinical rheumatoid arthritis lower vitamin D levels ([@b18-jer-12-6-610]).

Moreover, in Nurses' Health Study (NHS) and Nurses' Health Study II (NHS II) cohort studies confirmed the relationship between the incidence of rheumatoid arthritis and vitamin D intake. There was no significant association between the incidence of rheumatoid arthritis and in NHS II, even with an intake of 400 IU/day or more of vitamin D, resulted in an increase in rheumatoid arthritis ([@b8-jer-12-6-610]). A randomized double-blind placebo-controlled study of vitamin D in patients with rheumatoid arthritis for 12 months showed that vitamin D treatment was not effective in improving parathyroid hormone, bone mineral density, disease activity and cytokines in patients with rheumatoid arthritis ([@b15-jer-12-6-610]).

Although there was no statistically significant difference between the two groups, fertile period female group had higher odds ratios of rheumatoid arthritis at lower vitamin D levels, whereas postmenopausal period female group showed lower odds ratios of rheumatoid arthritis at lower levels of vitamin D, in this study. The incidence of rheumatoid arthritis is high in case of nulliparity or when there was no experience of oral contraceptive use ([@b14-jer-12-6-610]), or when breastfeeding is not performed after first birth ([@b6-jer-12-6-610]) Thus, female hormone changes have been reported to affect the risk of rheumatoid arthritis. Interactions between the endocrine system and the immune system are the basis for causing differences in the development of autoimmune diseases in women of childbearing and postmenopausal age. Diseases, induced by B cells, peak at reproductive years in women due to the effects of serum estrogens and their metabolites synthesized by the endocrine system. After that, the role of endocrine system decreases with age. When women become older and the majority of estrogen is made at a peripheral aromatase, the immune and inflammatory responses of men and women become similar ([@b11-jer-12-6-610]). Calcitriol (1,25(OH)2D3) inhibits the expression of aromatase, an enzyme that catalyzes the production of estrogen at the periphery, using androgen under normal conditions ([@b11-jer-12-6-610]). The high prevalence of autoimmune rheumatoid disease in women is due to a decrease in the down regulation of aromatase due to the deficiency of calcitriol (1,25(OH)2D3), leading to an increase in estrogen production in the periphery, which increases the risk and severity of rheumatoid arthritis ([@b22-jer-12-6-610]).

The present study showed that the relationship between vitamin D levels and pain was statistically significant in postmenopausal period rheumatoid arthritis female group. However, there was no significant difference in linear trend between pain and vitamin D level. Severe deficiency of vitamin D (\<10 ng/mL) is associated with symptoms such as musculoskeletal pain and symptomatic improvement in vitamin D supplementation has been reported ([@b16-jer-12-6-610]). However, a randomized, double-blind, placebo-controlled study reported no significant trends in patients' self-reported health status and visual pain rating (VAS), which were reported to be significantly worse in the vitamin-supplemented group ([@b15-jer-12-6-610]).

In the present study, there was no difference in quality of life according to the level of vitamin D. In some studies, univariate analysis showed an inverse correlation with increased functional impairment at low vitamin D levels. However, there was no significant difference in multivariate analysis ([@b1-jer-12-6-610]). The limitations of this study are that despite the data for many years, the actual number of patients with rheumatoid arthritis is not large enough, and seasonal effects, sun exposure time, use of drugs, such as disease modifying antirheumatic drugs or glucocorticoids, were not controlled.

The current recommendation for vitamin D supplements focuses on bone mineral density and fracture, and [@b30-jer-12-6-610] recommends a daily intake of 800 IU of vitamin D. Although vitamin D has not been statistically associated with the development of rheumatoid arthritis, it has been reported that vitamin D may be an appropriate adjuvant therapy for patients with rheumatoid arthritis due to its low cost and harmless ([@b12-jer-12-6-610]).

The results of this study showed that there was no difference in the incidence of rheumatoid arthritis according to the level of vitamin D in Korean adult women and that there was no difference in pain and quality of life when rheumatoid arthritis occurred. However, it is necessary to clarify the relationship through a large-scale cohort study that reflects the results of recently reported genome studies. Considering the effect of vitamin D supply on bone density and fracture, and the low price, vitamin D administration with effectiveness analysis is also needed.
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###### 

Characteristics of participants

  Period                  Percentile   No. of unweighted participants   Age (yr)      Body mass index (kg/m^2^)   Vitamin D (ng/mL)   Rheumatoid arthritis patients (%)[a)](#tfn2-jer-12-6-610){ref-type="table-fn"}   Present smoking (%)[a)](#tfn2-jer-12-6-610){ref-type="table-fn"}
  ----------------------- ------------ -------------------------------- ------------- --------------------------- ------------------- -------------------------------------------------------------------------------- ------------------------------------------------------------------
  Female                  1st          396                              39.02±0.82    22.92±0.22                  8.52±0.08           10.3                                                                             8.8
  2nd                     426          40.42±0.82                       22.78±0.24    11.94±0.04                  9.0                 8.7                                                                              
  3rd                     433          41.14±0.75                       23.13±0.22    14.66±0.04                  10.9                6.3                                                                              
  4th                     419          43.45±0.84                       23.19±0.22    17.91±0.07                  14.3                6..9                                                                             
  5th                     488          49.56±0.77                       23.23±0.18    25.97±0.30                  15.2                6.0                                                                              
  Total                   2,162        42.72±0.32                       23.05±0.10    15.80±0.19                  12.0                7.3                                                                              
                                                                                                                                                                                                                       
  Fertile period          1st          220                              33.24±0.77    22.50±0.30                  8.15±0.09           6.1                                                                              10.0
  2nd                     235          32.41±0.73                       22.54±0.43    11.29±0.05                  5.0                 8.8                                                                              
  3rd                     241          33.24±0.63                       22.47±0.24    13.83±0.05                  6.3                 7.5                                                                              
  4th                     233          34.02±0.66                       22.44±0.32    16.59±0.07                  7.0                 6.9                                                                              
  5th                     250          35.35±0.72                       22.70±0.25    22.85±0.34                  4.2                 9.1                                                                              
  Total                   1,179        33.66±0.27                       22.53±0.14    14.54±0.21                  5.7                 8.5                                                                              
                                                                                                                                                                                                                       
  Postmenopausal period   1st          199                              57.24±0.98    23.99±0.30                  9.44±0.13           20.4                                                                             5.9
  2nd                     192          56.98±0.95                       23.82±0.28    13.25±0.07                  18.5                9.1                                                                              
  3rd                     185          57.74±0.95                       24.01±0.28    16.53±0.09                  28.8                5.2                                                                              
  4th                     198          58.46±0.78                       24.39±0.29    20.55±0.13                  20.0                3.3                                                                              
  5th                     209          59.41±0.87                       23.39±0.24    29.75±0.44                  24.5                3.8                                                                              
  Total                   983          57.97±0.31                       23.92±0.123   17.92±0.2.94                22.4                5.5                                                                              

Values are presented as mean±standard error.

Percentages were calculated by weighted number.

###### 

Association between rheumatoid arthritis and vitamin D status

  Period                                               Percentile   Crude                Model 1              Model 2                                                                                               
  ---------------------------------------------------- ------------ -------------------- -------------------- --------- -------------------- -------------------- ------- -------------------- -------------------- -------
  Female                                               1st          20.0                 0.629 (0.40--0.99)   0.043     20.0                 1.194 (0.74--1.93)   0.469   20.0                 1.167 (0.72--1.89)   0.530
  2nd                                                  19.9         0.551 (0.36--0.85)   0.007                19.9      0.914 (0.58--1.44)   0.699                19.9    0.913 (0.58--1.44)   0.696                
  3rd                                                  20.0         0.686 (0.44--1.07)   0.097                20.0      1.154 (0.72--1.86)   0.555                20.0    1.153 (0.72--1.85)   0.556                
  4th                                                  20.1         0.913 (0.57--1.47)   0.710                20.1      1.330 (0.80--2.21)   0.269                20.1    1.329 (0.80--2.20)   0.268                
  5th                                                  20.0         Reference                                 20.0      Reference                                 20.0    Reference                                 
  Total[c)](#tfn6-jer-12-6-610){ref-type="table-fn"}   2,162                                                  2,162                                               2,160                                             
                                                                                                                                                                                                                    
  Fertile period                                       1st          19.9                 1.470 (0.65--3.34)   0.357     19.9                 1.647 (0.70--3.86)   0.249   19.9                 1.651 (0.70--3.88)   0.249
  2nd                                                  20.1         1.202 (0.52--2.78)   0.667                20.1      1.405 (0.59--3.35)   0.442                20.1    1.408 (0.59--3.37)   0.441                
  3rd                                                  20.0         1.526 (0.65--3.58)   0.331                20.0      1.750 (0.73--4.21)   0.211                20.0    1.764 (0.73--4.27)   0.207                
  4th                                                  20.0         1.696 (0.73--3.94)   0.219                20.0      1.870 (0.78--4.48)   0.160                20.0    1.887 (0.78--4.54)   0.156                
  5th                                                  20.0         Reference                                 20.0      Reference                                 20.0    Reference                                 
  Total[c)](#tfn6-jer-12-6-610){ref-type="table-fn"}   1,179                                                  1,179                                               1,179                                             
                                                                                                                                                                                                                    
  Postmenopausal period                                1st          20.0                 0.790 (0.45--1.40)   0.416     20.0                 0.864 (0.49--1.53)   0.615   19.9                 0.841 (0.47--1.49)   0.554
  2nd                                                  20.0         0.698 (0.41--1.19)   0.183                20.0      0.773 (0.46--1.32)   0.342                20.0    0.775 (0.46--1.30)   0.335                
  3rd                                                  20.0         1.247 (0.67--2.33)   0.488                20.0      1.400 (0.73--2.68)   0.310                20.0    1.404 (0.74--2.68)   0.302                
  4th                                                  19.9         0.768 (0.44--1.35)   0.358                19.9      0.792 (0.45--1.38)   0.411                20.0    0.796 (0.46--1.37)   0.412                
  5th                                                  20.1         Reference                                 20.1      Reference                                 20.1    Reference                                 
  Total[c)](#tfn6-jer-12-6-610){ref-type="table-fn"}   983                                                    983                                                 981                                               

Model 1 was adjusted for age. Model 2 was adjusted for age and body mass index.

Crude and each model's odds ratios (ORs) and 95% confidence intervals (95% CIs) calculated by Complex samples logistic regression analysis.

Percentage of participants in each percentiles were calculated by weighted number.

Unweighted number.

###### 

Association between rheumatoid arthritis' visual analogue scale and vitamin D status

  Patient                                               Percentile   Crude                                                      Model 1      Model 2                                                                 
  ----------------------------------------------------- ------------ ---------------------------------------------------------- ------------ --------- ------------- ------------ ------- ------------- ------------ -------
  Female rheumatoid arthritis patients                  1st          18.6                                                       62.19±3.47   0.519     18.6          60.23±3.55   0.400   18.3          59.47±3.59   0.315
  2nd                                                   20.3         70.81±3.42                                                              20.3      69.87±3.36                 20.4    69.85±3.32                 
  3rd                                                   19.1         67.07±5.93                                                              19.1      67.19±5.82                 19.2    67.16±5.81                 
  4th                                                   20.3         65.11±3.98                                                              20.3      65.46±3.81                 20.3    65.44±3.80                 
  5th                                                   21.7         65.11±3.94                                                              21.7      67.25±3.88                 21.8    67.43±3.92                 
  Total[c)](#tfn10-jer-12-6-610){ref-type="table-fn"}   283                                                                                  283                                  281                                
                                                                                                                                                                                                                     
  Fertile rheumatoid arthritis patients                 1st          20.1                                                       67.84±3.66   0.454     20.1          68.29±2.73   0.504   20.1          68.54±3.65   0.710
  2nd                                                   22.4         69.80±4.09                                                              22.4      69.99±4.15                 22.4    70.00±4.12                 
  3rd                                                   20.7         77.07±4.69                                                              20.7      76.40±4.33                 20.7    76.25±4.66                 
  4th                                                   18.5         54.98±13.36                                                             18.5      55.33±13.63                18.5    55.37±13.79                
  5th                                                   18.3         73.19±3.49                                                              18.3      72.88±3.32                 18.3    72.71±3.52                 
  Total[c)](#tfn10-jer-12-6-610){ref-type="table-fn"}   71                                                                                   71                                   71                                 
                                                                                                                                                                                                                     
  Postmenopausal rheumatoid arthritis patients          1st          17.3                                                       59.55±4.17   0.031     17.3          58.63±4.02   0.022   16.8          57.65±4.07   0.015
  2nd                                                   19.6         64.75±4.44                                                              19.6      66.40±4.22                 19.7    66.33±4.12                 
  3rd                                                   21.5         75.85±3.65[d)](#tfn11-jer-12-6-610){ref-type="table-fn"}                21.5      72.71±2.46                 21.7    72.79±2.49                 
  4th                                                   20.5         60.45±5.09                                                              20.5      62.42±5.56                 20.6    62.34±5.49                 
  5th                                                   21.1         62.84±5.32                                                              21.1      63.37±4.88                 21.2    63.38±4.85                 
  Total[c)](#tfn10-jer-12-6-610){ref-type="table-fn"}   212                                                                                  212                                  210                                

Model 1 was adjusted for age. Model 2 was adjusted for age and body mass index.

Crude and each model's means, standard errors, and *P*-value were calculated by complex samples general linear analysis.

The percentage of participants in each percentiles were calculated by weighted number.

Unweighted number.

Compared to 5th percentile group.

###### 

Association between rheumatoid arthritis' EQ-5D index and vitamin D status

  Patient                                               Percentile   Crude       Model 1                                                   Model 2                                                                                                         
  ----------------------------------------------------- ------------ ----------- --------------------------------------------------------- --------- ----------- --------------------------------------------------------- ------- ----------- ----------- -------
  Female rheumatoid arthritis patients                  1st          19.6        0.85±0.03                                                 0.822     19.6        0.84±0.03                                                 0.675   19.3        0.84±0.04   0.755
  2nd                                                   19.6         0.88±0.02                                                             19.6      0.88±0.02                                                             20.0    0.88±0.02               
  3rd                                                   20.1         0.83±0.05                                                             20.1      0.83±0.05                                                             20.1    0.83±0.05               
  4th                                                   20.1         0.88±0.03                                                             20.1      0.88±0.03                                                             20.2    0.88±0.02               
  5th                                                   20.4         0.86±0.03                                                             20.4      0.88±0.03                                                             20.4    0.87±0.03               
  Total[c)](#tfn14-jer-12-6-610){ref-type="table-fn"}   319                                                                                319                                                                             317                             
                                                                                                                                                                                                                                                           
  Fertile rheumatoid arthritis patients                 1st          19.7        0.92±0.01[d)](#tfn15-jer-12-6-610){ref-type="table-fn"}   0.025     19.7        0.92±0.01[d)](#tfn15-jer-12-6-610){ref-type="table-fn"}   0.048   19.7        0.94±0.02   0.165
  2nd                                                   19.9         0.94±0.01                                                             19.9      0.94±0.01                                                             19.9    0.95±0.02               
  3rd                                                   20.4         0.93±0.02                                                             20.4      0.93±0.02                                                             20.4    0.91±0.03               
  4th                                                   20.2         0.73±0.12                                                             20.2      0.73±0.12                                                             20.2    0.74±0.11               
  5th                                                   19.8         0.96±0.01                                                             19.8      0.96±0.01                                                             19.8    0.94±0.02               
  Total[c)](#tfn14-jer-12-6-610){ref-type="table-fn"}   80                                                                                 80                                                                              80                              
                                                                                                                                                                                                                                                           
  Postmenopausal rheumatoid arthritis patients          1st          19.7        0.81±0.04                                                 0.244     19.7        0.80±0.04                                                 0.570   19.3        0.80±0.04   0.673
  2nd                                                   20.2         0.83±0.02                                                             20.2      0.84±0.02                                                             20.3    0.85±0.02               
  3rd                                                   20.2         0.90±0.03                                                             20.2      0.88±0.03                                                             20.3    0.87±0.03               
  4th                                                   20.0         0.82±0.03                                                             20.0      0.84±0.04                                                             20.1    0.85±0.03               
  5th                                                   19.9         0.86±0.04                                                             19.9      0.87±0.03                                                             20.0    0.86±0.03               
  Total[c)](#tfn14-jer-12-6-610){ref-type="table-fn"}   239                                                                                239                                                                             237                             

Crude and each model's means, standard errors, and *P*-value were calculated by complex samples general linear analysis.

The percentage of participants in each percentiles were calculated by weighted number.

Unweighted number.

Compared to 5th percentile group.

Model 1 was adjusted for age. Model 2 was adjusted for age and body mass index.
